3,3,3-trifluoro-2,2-dimethylpropanoic acid is a useful trifluoromethylated building block for the synthesis of various pharmaceutically active compounds, such as beta-secretase modulators, ion-channel ligands, GPR119 agonists, JAK and SYK inhibitors, SGC stimulators,dual inhibitors of neutrophil elastase and proteinase 3 and inhibitors of the microsomal prostaglandin E2 synthase-1, etc..
Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists. 
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP- 324 96), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.
Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.
A concise one-pot synthesis of trifluoromethyl-containing 2,6-disubstituted 5,6,7,8-tetrahydroquinolines and 5,6,7,8-tetrahydronaphthyridines.
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection.
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.
Near-Infrared Fluorescence of Silicon Phthalocyanine Carboxylate Esters.